Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis.

Brinkman IH, van de Laar MA, Jansen TL, van Roon EN.

Expert Opin Drug Saf. 2011 Sep;10(5):715-26. doi: 10.1517/14740338.2011.562188. Epub 2011 Mar 15. Review.

PMID:
21401437
2.

B-cell therapies in established rheumatoid arthritis.

Leandro MJ, Becerra-Fernandez E.

Best Pract Res Clin Rheumatol. 2011 Aug;25(4):535-48. doi: 10.1016/j.berh.2011.10.005. Review.

PMID:
22137923
3.

[Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].

Hernández-Cruz B, García-Arias M, Ariza Ariza R, Martín Mola E.

Reumatol Clin. 2011 Sep-Oct;7(5):314-22. doi: 10.1016/j.reuma.2011.03.004. Epub 2011 Aug 2. Review. Spanish.

4.

[B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].

Yukawa N, Mimori T.

Clin Calcium. 2007 Apr;17(4):569-76. Review. Japanese.

PMID:
17404487
5.

Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.

Bredemeier M, de Oliveira FK, Rocha CM.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):228-35. doi: 10.1002/acr.22116.

6.

Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort.

Slimani S, Lukas C, Combe B, Morel J.

Joint Bone Spine. 2011 Oct;78(5):484-7. doi: 10.1016/j.jbspin.2010.11.012. Epub 2010 Dec 31.

PMID:
21196130
7.

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).

Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, Collinson N, Shaw TM; MIRROR Trial Investigators.

Rheumatology (Oxford). 2010 Sep;49(9):1683-93. doi: 10.1093/rheumatology/keq116. Epub 2010 May 12.

8.

[Consensus on the Use of Rituximab in Rheumatoid Arthritis. A document with evidence-based recommendations. Grupo de Expertos en Rituximab. ].

Martín Mola E, Hernández B, García-Arias M, Alvaro-Gracia JM, Balsa A, Reino JG, Marenco de la Fuente JL, Martínez-Taboada V, Ivorra JA, Sanmartí R; el grupo de Expertos en Rituximab.

Reumatol Clin. 2011 Jan-Feb;7(1):30-44. doi: 10.1016/j.reuma.2010.11.002. Epub 2010 Dec 17. Spanish.

9.

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB.

Ann Rheum Dis. 2013 Sep 1;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956. Epub 2012 Nov 7.

10.
11.

Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?

Benucci M, Manfredi M, Puttini PS, Atzeni F.

Autoimmun Rev. 2010 Oct;9(12):801-3. doi: 10.1016/j.autrev.2010.07.006. Epub 2010 Jul 23. Review.

PMID:
20656069
12.

Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab.

Abdulkader R, Dharmapalaiah C, Rose G, Shand LM, Clunie GP, Watts RA.

J Rheumatol. 2014 May;41(5):858-61. doi: 10.3899/jrheum.130526. Epub 2014 Mar 15.

PMID:
24634201
13.

Rituximab for rheumatoid arthritis.

Palylyk-Colwell E, McGahan L.

Issues Emerg Health Technol. 2006 Sep;(89):1-4.

PMID:
17014062
14.

Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab.

de la Torre I, Leandro MJ, Edwards JC, Cambridge G.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4):554-60. Epub 2012 Aug 29.

PMID:
22510323
15.

Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.

Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP; RESET Investigators.

J Rheumatol. 2011 Dec;38(12):2548-56. doi: 10.3899/jrheum.110444. Epub 2011 Oct 1.

16.

B-cell therapies for rheumatoid arthritis.

Scher JU.

Bull NYU Hosp Jt Dis. 2012;70(3):200-3. Review.

17.

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.

Mariette X, Gottenberg JE, Ravaud P, Combe B.

Rheumatology (Oxford). 2011 Jan;50(1):222-9. doi: 10.1093/rheumatology/keq368.

18.

Non-infectious pulmonary toxicity of rituximab: a systematic review.

Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ.

Rheumatology (Oxford). 2012 Apr;51(4):653-62. doi: 10.1093/rheumatology/ker290. Epub 2011 Dec 7. Review.

19.

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

Leandro MJ, Edwards JC, Cambridge G.

Ann Rheum Dis. 2002 Oct;61(10):883-8.

20.

Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis.

Roll P, Mahmood Z, Muhammad K, Feuchtenberger M, Dörner T, Tony HP.

Clin Exp Rheumatol. 2015 May-Jun;33(3):347-53. Epub 2015 Apr 16.

PMID:
25897997
Items per page

Supplemental Content

Write to the Help Desk